U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06927635) titled 'Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer' on March 03.
Brief Summary: This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Castrate Resistance Prostate Cancer
OligoProgressi...